Clinical Trials
309 trialsNovel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
University of Florida
Study of MEDI0562 Prior to Surgical Resection in Head and Neck Squamous Cell Carcinoma (HNSCC) or Melanoma
Providence Health & Services
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
M.D. Anderson Cancer Center
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
LauT1
Centre Hospitalier Universitaire Vaudois
PanRAF
Royal Marsden NHS Foundation Trust
Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases
M.D. Anderson Cancer Center
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
M.D. Anderson Cancer Center
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases
Emory University
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA)
M.D. Anderson Cancer Center
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
M.D. Anderson Cancer Center
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
M.D. Anderson Cancer Center
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase Ib of L-NMMA and Pembrolizumab
The Methodist Hospital Research Institute
Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
M.D. Anderson Cancer Center
Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma
H. Lee Moffitt Cancer Center and Research Institute
TICIMEL
Institut Claudius Regaud
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Dana-Farber Cancer Institute
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
REPLAY
Duke University
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
Ohio State University Comprehensive Cancer Center
Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Emory University
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
IKKb-matured, RNA-loaded Dendritic Cells for Metastasised Uveal Melanoma
Hasumi International Research Foundation
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Ohio State University Comprehensive Cancer Center
Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
University of Kentucky
A Study of CD45RA+ Depleted Haploidentical Stem Cell Transplantation in Children With Relapsed or Refractory Solid Tumors and Lymphomas
St. Jude Children's Research Hospital
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
Memorial Sloan Kettering Cancer Center
TGI5
Hefei TG ImmunoPharma Co., Ltd.
Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy
City of Hope Medical Center
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
Mayo Clinic
Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Mayo Clinic
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
CARE-Melanoma
McMaster University
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
Dana-Farber Cancer Institute
A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
Dana-Farber Cancer Institute
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
Intra-Lymphatic STI-3031 Using the Sofusa DoseConnect Device for Treatment of In-Transit Melanoma, The Sofusa-2 Study
Mayo Clinic
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Memorial Sloan Kettering Cancer Center